Condition: Lymphoma · Multiple Myeloma · Leukemia · Sponsor: First Affiliated Hospital of Fujian Medical University
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.
This description comes directly from the study's public registry record.
Weibing Miao, M.D. · +86-599-87981618 · miaoweibing@126.com
Zhenying Chen · +86-599-87981619 · chenzhenying726@foxmail.com
Always discuss trial participation with your own doctor first.
| Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504526